Expansion of Cell Bank Manufacturing Capacity and Capabilities in North America
In an effort to increase efficiencies and capacity, Charles River Laboratories will add a third, state-of-the-art cleanroom suite dedicated to virus seed and vaccine candidate manufacturing to its Malvern, Pennsylvania facility. This large cleanroom suite hosts additional manufacturing equipment, yielding an increased capacity to scale virus seed stocks and vaccine candidates. The space also houses refrigerated incubators for the cultivation of insect cell lines. These capabilities play a significant role in the gene therapy space, which are being used as a host cell for campaigns and manufacturing programs utilizing a baculovirus expression system. We also upgraded two of our mammalian cleanroom suites (scheduled to go online in Q4, 2021). The upgrade allows for increased output and offers greater risk mitigation due to redundancies in equipment/infrastructure.
Cell Bank Manufacturing Added in Europe
In addition to the expansion in North America, we now offer cell bank manufacturing and storage in Europe via our recent Cobra Biologics acquisition. Cobra provides cell banking and viral seed stock production to support customers’ projects from pre-clinical, clinical Phase I, II, and III to commercial-scale supply.
Are you in need of a cell bank manufacturing and storage in the near future?